Multiregional Clinical Trials: Japanese Perspective on Drug Development Strategy and Sample Size for Japanese Subjects
Authors:
- 1 September 2012
- journal article
- review article
- Published by Taylor & Francis in Journal of Biopharmaceutical Statistics
- Vol. 22 (5) , 977-987
Abstract
Multiregional clinical trials including Japanese subjects are playing a key role in new drug development in Japan. In addition to the consideration of differences in intrinsic and extrinsic ethnic factors, deciding the sample size of Japanese subjects is an important issue when a multiregional clinical trial is intended to be used for Japanese submission. Accumulated experience suggests that there are several points to consider, such as the basic principles described in the guidance document, drug development strategy, trial phase, and disease background. The difficulty of interpreting the results of Japanese trials should also be considered.Keywords
This publication has 7 references indexed in Scilit:
- Practical issues and lessons learned from multi‐regional clinical trials via case examples: a Japanese perspectivePharmaceutical Statistics, 2010
- Exploring Differences in Drug Doses Between Japan and Western CountriesClinical Pharmacology & Therapeutics, 2010
- Sample size considerations for Japanese patients in a multi‐regional trial based on MHLW guidancePharmaceutical Statistics, 2010
- Effective Global Drug Development Strategy for Obtaining Regulatory Approval in Japan in the Context of Ethnicity-Related Drug Response FactorsClinical Pharmacology & Therapeutics, 2010
- Same Drug, Different Dosing: Differences in Dosing for Drugs Approved in the United States, Europe, and JapanThe Journal of Clinical Pharmacology, 2008
- Development of Triptans in Japan: Bridging Strategy Based on the ICH-E5 GuidelineJournal of Health Science, 2006
- Successful bridging strategy based on ICH E5 guideline for drugs approved in JapanClinical Pharmacology & Therapeutics, 2005